🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Adjuvanted pandemic influenza candidate vaccine

Found 13 matching trials

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

PHASE3

The present study will evaluate the immunogenicity, safety and immunogenici...

Status

Completed

Location

Vaccination and Travel Medicine Centre

Start Date

2008-11

Trial ID

NCT00848029

Treatments Being Tested

Monovalent inactivated influenza vaccine

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

PHASE1

Today, the leading contender for the next pandemic of influenza is H5N1, a ...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-03-27

Trial ID

NCT00309634

Treatments Being Tested

4 adjuvanted pandemic influenza candidate vaccines 4 non-adjuvanted pandemic influenza candidate vaccines

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

PHASE2

Influenza pandemics are caused by viruses that possess an Hemagglutinin mol...

Status

Completed

Location

GSK Investigational Site

Start Date

2005-05-11

Trial ID

NCT00306995

Treatments Being Tested

SB218352_15 SB218352_8 SB218352_4 SB218352_2 SB218352_8AL SB218352_4AL SB218352_2AL

Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

PHASE3

Today, the leading contender for the next influenza pandemic is H5N1, a str...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-03-23

Trial ID

NCT00652743

Treatments Being Tested

Pandemic influenza vaccine GSK1562902A

Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines

PHASE1

This is a prospective phase I study to evaluate the safety, tolerability an...

Status

Completed

Location

Centro de Pesquisa Clinica do Instituto da Criança do hospital das Clinicas da Faculdade de Medicina da USP

Start Date

2010-01

Trial ID

NCT01111968

Treatments Being Tested

pandemic vaccine 1 pandemic vaccine 2 pandemic vaccine 5 pandemic vaccine 6 pandemic vaccine 9 pandemic vaccine 10 pandmeic vaccine 11 pandmeic vaccine 12 pandmic vaccine 13 placebo group 14

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

PHASE2

The present study is designed to evaluate in children (aged between 3 and 9...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-07-23

Trial ID

NCT00502593

Treatments Being Tested

Pandemic Influenza Vaccine (GSK1562902A)Fluarix™

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

PHASE3

Today, the leading contender for the next pandemic of influenza is H5N1, a ...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-05-01

Trial ID

NCT00319098

Treatments Being Tested

Adjuvanted pandemic influenza candidate vaccine Fluarix Placebo

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

PHASE2

The purpose of this study is to show that vaccination with a single dose of...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-02-01

Trial ID

NCT01035749

Treatments Being Tested

GSK Biologicals' Influenza investigational vaccine GSK2340274A GSK Biologicals' Influenza investigational vaccine GSK2340273A Placebo (saline)

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

PHASE2

The present study will evaluate the immunogenicity, safety and tolerability...

Status

Completed

Location

Pestlőrinc-Pestszentimre Egészségügyi Szolgáltató KFT

Start Date

2008-12

Trial ID

NCT00841646

Treatments Being Tested

Monovalent inactivated influenza vaccine

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

PHASE3

The present study is designed to assess the lot-to-lot consistency of the i...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-03-24

Trial ID

NCT00449670

Treatments Being Tested

H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)

Previous Next